Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04589650 |
| Consolidated Lead Sponsor | Novartis |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 236 participants (ACTUAL) |
| Registered Start Date | 2021-04-19 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| University of North Carolina at Chapel Hill | Chapel Hill, NC | Open Hospital Dossier -> |
| Cincinnati Children's Hospital Medical Center | Cincinnati, OH | Open Hospital Dossier -> |
| Baylor College of Medicine | Houston, TX | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.